Pfizer announced a $43 billion deal to acquire Seagen, a leading developer of antibody–drug conjugates. The move comes as Pfizer faces a looming “patent cliff” in oncology, with exclusivity soon to expire for several of its top-selling cancer therapies.

You do not currently have access to this content.